Physicians' Academy for Cardiovascular Education

Landmark Statin Trials Across the Spectrum of Risk: Secondary Stroke Prevention

Slides (presentation) - Dec. 23, 2012

Slide lecture program (12 slides): View & Download

  1. Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
  2. SPARCL Trial of Secondary Stroke Prevention: Study Design
  3. SPARCL Primary End Point: Time to Fatal or Nonfatal Stroke
  4. SPARCL Secondary End Point: Time to Major Coronary Event
  5. SPARCL: Benefit/Risk
  6. Effect of Atorvastatin on Stroke In SPARCL Patients with Diabetes
  7. SPARCL: Stroke in Patients With Carotid Stenosis
  8. SPARCL: Carotid Endarterectomy in Patients with Carotid Stenosis
  9. SPARCL: Prespecified and Post-Hoc Analyses
  10. SPARCL: Ischemic and Hemorrhagic Stroke Post hoc Analysis
  11. SPARCL: Multivariable Cox Regression Model Baseline Characteristics

Click on slides to preview

Download slides below

Landmark Statin Trials Across the Spectrum of Risk
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
SPARCL Trial of Secondary Stroke Prevention: Study Design
SPARCL Primary End Point: Time to Fatal or Nonfatal Stroke
SPARCL Secondary End Point: Time to Major Coronary Event
SPARCL: Benefit/Risk
Effect of Atorvastatin on Stroke In SPARCL Patients with Diabetes
SPARCL: Stroke in Patients With Carotid Stenosis
SPARCL: Carotid Endarterectomy in Patients with Carotid Stenosis
SPARCL: Prespecified and Post-Hoc Analyses
SPARCL: Ischemic and Hemorrhagic Stroke Post hoc Analysis
SPARCL: Multivariable Cox Regression Model Baseline Characteristics

Share this page with your colleagues and friends: